Peptides Similar to GHRP-2

Peptides Related to GHRP-2#

GHRP-2 belongs to the growth hormone secretagogue (GHS) peptide family, a class of synthetic peptides that stimulate growth hormone release through activation of the GHS-R1a (ghrelin) receptor on pituitary somatotrophs and hypothalamic neurons. Several other GHS peptides share this mechanism of action but differ in their potency, selectivity, secondary hormonal effects, and clinical development status. Understanding these comparative profiles is essential for evaluating GHRP-2's position within the GHS landscape.

The primary comparators for GHRP-2 are hexarelin (the most potent GHRP), GHRP-6 (the first-generation prototype), and ipamorelin (the most selective GHS). All four peptides share the same primary receptor target (GHS-R1a) and fundamental mechanism of GH release, but they differ meaningfully in their off-target effects on cortisol, prolactin, aldosterone, and appetite -- differences that have significant implications for research applications and clinical utility.

Hexarelin#

Structural and Mechanistic Comparison#

Hexarelin (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide GHS that shares the same core tetrapeptide sequence (Ala-Trp-D-Phe-Lys-NH2) with GHRP-2 at positions 3-6. The key structural differences are at positions 1 and 2: hexarelin has L-Histidine and D-2-methyltryptophan, whereas GHRP-2 has D-Alanine and D-2-naphthylalanine. The 2-methyltryptophan modification in hexarelin confers exceptionally high GHS-R1a binding affinity, making hexarelin the most potent GHRP in terms of acute GH release.

Both peptides activate GHS-R1a and engage the Gq/11-PLC-IP3 signaling cascade. However, hexarelin also binds to CD36 (cluster of differentiation 36), a scavenger receptor expressed on cardiac and vascular cells. This CD36-mediated activity underlies hexarelin's unique cardioprotective effects, including reduced infarct size, improved cardiac contractility, and anti-atherosclerotic properties observed in preclinical studies. GHRP-2 does not share this CD36 binding activity.

GH Potency and Selectivity#

In head-to-head clinical comparisons, hexarelin generally produces higher peak GH levels than GHRP-2 at equivalent doses. However, hexarelin also stimulates significantly more cortisol and prolactin release, reflecting broader activation of pituitary cell types beyond somatotrophs. This wider hormonal footprint makes hexarelin less selective as a GH secretagogue and introduces confounding variables in research settings focused specifically on GH axis physiology.

GHRP-2 offers a more favorable selectivity profile, producing robust GH release with comparatively modest cortisol and prolactin elevation. For research applications where clean GH stimulation is desired without substantial cortisol or prolactin perturbation, GHRP-2 is generally preferred over hexarelin.

Tachyphylaxis#

Both hexarelin and GHRP-2 exhibit tachyphylaxis (reduced response) with repeated daily administration, a phenomenon attributed to GHS-R1a internalization and upregulation of somatostatin tone. However, hexarelin appears to undergo more rapid desensitization than GHRP-2. Clinical studies have shown that the GH response to hexarelin diminishes substantially within 1-2 weeks of daily dosing, whereas GHRP-2 maintains a somewhat more sustained response over the same period, although desensitization still occurs.

Comparative Summary#

GHRP-6#

Structural and Historical Context#

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) is the first-generation growth hormone releasing peptide and the prototype of the GHRP family. It was among the earliest synthetic GHS peptides studied by Bowers and colleagues and served as the structural starting point from which GHRP-2 was developed through systematic optimization. GHRP-6 and GHRP-2 share the identical C-terminal tetrapeptide (Ala-Trp-D-Phe-Lys-NH2) but differ at positions 1 and 2, where GHRP-6 has His-D-Trp and GHRP-2 has D-Ala-D-2-Nal.

The replacement of D-Trp with D-2-Nal at position 2 in GHRP-2 was a critical optimization that enhanced GHS-R1a binding affinity and GH-releasing potency. The substitution of His with D-Ala at position 1 further improved metabolic stability by providing N-terminal protease resistance through the D-configuration.

GH Potency and Selectivity Differences#

GHRP-2 is more potent than GHRP-6 on a per-molar basis for GH release. Clinical pharmacology studies comparing the two peptides at matched doses have shown that GHRP-2 produces higher peak GH concentrations with lower stimulation of cortisol and prolactin. GHRP-6 produces a broader hormonal response that includes more pronounced cortisol, prolactin, and aldosterone elevation.

The appetite-stimulating effects of GHRP-6 are notably stronger than those of GHRP-2. GHRP-6 is one of the most potent orexigenic GHS peptides, reliably increasing hunger and food intake in both animal and human studies. This effect is mediated through GHS-R1a activation on hypothalamic NPY/AgRP neurons. While GHRP-2 also stimulates appetite via the same mechanism, the effect is less pronounced, likely reflecting differences in hypothalamic receptor engagement between the two peptides.

Research and Clinical Applications#

GHRP-6 has been extensively used in preclinical research as a tool compound for studying GHS-R1a pharmacology and GH axis physiology. Its strong appetite-stimulating properties have made it particularly useful in cachexia and anorexia research models where orexigenic effects are desirable.

Neither GHRP-6 nor GHRP-2 is approved for therapeutic use in major pharmaceutical markets, but GHRP-2 holds a unique advantage as the only GHRP with any regulatory approval (diagnostic use in Japan as GHRP Kaken). GHRP-6 has not advanced to regulatory approval in any jurisdiction.

Comparative Summary#

Ipamorelin#

Structural and Mechanistic Comparison#

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a synthetic pentapeptide GHS that represents a further evolution of the GHRP structural class toward maximized selectivity. Unlike the hexapeptide GHRPs (GHRP-2, GHRP-6, hexarelin), ipamorelin contains five residues and incorporates alpha-aminoisobutyric acid (Aib) at position 1, a non-proteinogenic residue that provides exceptional protease resistance through gem-dimethyl substitution on the alpha-carbon.

Both GHRP-2 and ipamorelin activate GHS-R1a on pituitary somatotrophs, but ipamorelin appears to engage the receptor in a manner that minimizes secondary hormonal effects to a greater degree than any other GHS peptide. Ipamorelin produces GH release with virtually no concomitant stimulation of cortisol, prolactin, or aldosterone at doses that produce substantial GH elevation. This selectivity profile is unmatched among GHS peptides.

GH Potency and Selectivity#

GHRP-2 produces higher peak GH levels than ipamorelin at comparable doses, reflecting its greater intrinsic efficacy at GHS-R1a. However, ipamorelin's selectivity advantage is substantial: even at doses that maximize GH release, ipamorelin does not significantly elevate cortisol or prolactin above baseline. GHRP-2, while more selective than hexarelin or GHRP-6, does produce measurable cortisol and prolactin increases at GH-stimulatory doses.

The appetite-stimulating effects of ipamorelin are minimal compared to both GHRP-2 and GHRP-6. This makes ipamorelin better suited for research contexts where GH stimulation is desired without the confounding effects of altered feeding behavior.

Clinical Development Status#

Neither GHRP-2 nor ipamorelin is approved for therapeutic use outside of GHRP-2's diagnostic indication in Japan. Ipamorelin was investigated in Phase 2 clinical trials for post-operative ileus recovery, where its ability to stimulate GH release without broader hormonal perturbation was considered advantageous for the surgical patient population. However, these trials did not lead to regulatory approval, and clinical development appears to have stalled.

Comparative Summary#

Broader GHS Family Context#

Selectivity Spectrum#

The four GHS peptides discussed here span a spectrum of selectivity for GH release relative to off-target hormonal effects. Arranged from least selective to most selective:

1. GHRP-6: Broadest hormonal profile with significant cortisol, prolactin, and appetite effects alongside GH release
2. Hexarelin: High GH potency but substantial cortisol and prolactin stimulation; unique CD36 activity
3. GHRP-2: Favorable balance of potent GH release with modest secondary hormonal effects; the approved diagnostic agent
4. Ipamorelin: Most selective GHS with virtually no cortisol, prolactin, or appetite effects; lower absolute GH potency

This selectivity gradient reflects progressive structural optimization of the GHRP scaffold, with each generation refining the structure-activity relationships that govern GHS-R1a engagement while minimizing engagement of pathways responsible for off-target hormonal effects.

GHRH Synergy#

All GHS peptides demonstrate synergistic GH release when co-administered with GHRH or GHRH analogs, because GHS-R1a (Gq/PLC) and GHRH receptor (Gs/cAMP) signaling converge on somatotroph GH secretion through complementary intracellular pathways. GHRP-2 has been the most extensively studied GHS for GHRH synergy, particularly in the Japanese diagnostic context where the combined GHRH plus GHRP-2 stimulation test is used clinically to differentiate hypothalamic from pituitary causes of GH deficiency.

Non-Peptide GHS Comparators#

Beyond the peptide GHS family, non-peptide GHS-R1a agonists such as MK-677 (ibutamoren) offer oral bioavailability and longer duration of action. MK-677 produces sustained GH elevation over 24 hours with a single oral dose, compared to the 2-3 hour duration of action of intravenous or subcutaneous GHRP-2. However, MK-677's prolonged activity also produces sustained appetite stimulation and prolonged insulin resistance that are less prominent with the pulsatile GH elevation produced by intermittent GHRP-2 administration.

Evidence Gaps#

Definitive head-to-head comparisons of all four GHS peptides under standardized conditions in the same study population are limited. Most comparative data are derived from separate studies conducted by different groups with different protocols, patient populations, and GH assay methodologies. Standardized crossover studies comparing GHRP-2, hexarelin, GHRP-6, and ipamorelin at equipotent GH-stimulatory doses with comprehensive assessment of all secondary hormonal endpoints would provide the most rigorous basis for comparative evaluation, but such studies have not been published.

Related Reading#

• GHRP-2 overview and research guide
• GHRP-2 research evidence
• GHRP-2 dosing protocols